Compare TLIH & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TLIH | PLUR |
|---|---|---|
| Founded | 1998 | 2001 |
| Country | Singapore | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.1M | 34.9M |
| IPO Year | 2025 | N/A |
| Metric | TLIH | PLUR |
|---|---|---|
| Price | $0.36 | $3.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 270.3K | 58.1K |
| Earning Date | 09-30-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $51,204,304.00 | $1,326,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | $3.28 | ★ N/A |
| Revenue Growth | N/A | ★ 121.74 |
| 52 Week Low | $0.31 | $3.20 |
| 52 Week High | $7.00 | $7.13 |
| Indicator | TLIH | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 39.82 |
| Support Level | N/A | $3.20 |
| Resistance Level | N/A | $3.94 |
| Average True Range (ATR) | 0.00 | 0.37 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 0.00 | 9.61 |
Ten-League International Holdings Ltd is a Singapore-based provider of turnkey project solutions. Its business consists of sales of heavy equipment and parts, heavy equipment rental and provision of engineering consultancy services to port, construction, civil engineering and underground foundation industries. It currently conducts its operations through its wholly-owned subsidiaries. The equipment it provides is organized into four categories based on their functions and application scenarios, namely, foundation equipment, hoist equipment, excavation equipment and port machinery. The company operates in Singapore and Other International Countries.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.